+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia



Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia



Haematologica 96(9): 1390-1391




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052903834

Download citation: RISBibTeXText

PMID: 21659361

DOI: 10.3324/haematol.2011.045500


Related references

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Annals of Hematology 97(10): 1797-1802, 2018

Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Annals of Hematology 78(7): 329-332, 1999

Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Leukemia Research 66: 85-88, 2018

Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Leukemia Research 66: 85-88, 2018

Combination therapy with arsenic trioxide (ATO), all-trans retinoic acid (ATRA), and gemtuzumab ozogamycin (GO) in relapsed acute promyelocytic leukemia (APL). Journal of Clinical Oncology 24(18_Suppl): 6558-6558, 2016

Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL). Hospital Pharmacy 51(8): 628-632, 2016

Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 125(6): 389-396, 2005

Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL). Zhonghua Xue Ye Xue Za Zhi 24(1): 25-27, 2003

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Annals of Oncology 17(1): 131-134, 2006

Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment. Leukemia and Lymphoma 47(7): 1438-1440, 2006

Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 23(5): 1292-1295, 2015

Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As 2 O 3 ) combination therapy in newly diagnosed acute promyelocytic leukemia (APL). Journal of Clinical Oncology 24(18_Suppl): 6503-6503, 2016

First line treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and chemotherapy. 2007

Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leukemia Research 36(7): 841-845, 2012

Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia. British Journal of Haematology 111(4): 1103-1105, 2000